Synthetic lethality of decitabine plus ATR inhibition for TP53 -mutated AML
Open Access
- 6 April 2026
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (7) , 2506-2520
Abstract
TP53 mutations are found in 10% to 15% of myeloid neoplasms and are associated with a dismal prognosis. Although hypomethylating agents (HMAs), such as decitabine, are active in TP53-mutated myeloid neoplasms (TP53-MN), mutation clearance is rarely complete and nearly all patients relapse. Molecular determinants of response to HMAs in TP53-MN are poorly understood. Here, we show that decitabine induces replicative stress with decreased replication fork progression, induction of single-strand DNA breaks, and activation of the ataxia telangiectasia mutated–Rad3-related (ATR) pathway. Resolution of decitabine-induced replication stress is impaired in TP53-mutated acute myeloid leukemia (AML) cells, representing a potential therapeutic vulnerability. Indeed, the combination of decitabine and ATR inhibition (ATRi) induces synthetic lethality that is selective for TP53-AML and due, in part, to induction of mitotic catastrophe. Interestingly, this synergistic lethality was not observed with azacitidine or treatment with GSK3685032, a potent DNA methyltransferase 1 inhibitor, both of which produce a comparable level of global hypomethylation to decitabine. Treatment with decitabine and an ATR inhibitor reduces leukemia burden and prolongs survival in in vivo mouse models of TP53-mutated AML. Collectively, these findings show that TP53 loss generates a selective vulnerability to decitabine-induced replication stress, with the combination of ATRi and decitabine showing promise as a new therapeutic approach for TP53-MN.Keywords
This publication has 60 references indexed in Scilit:
- Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatmentCell Reports, 2023
- Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysisClinical Lymphoma Myeloma and Leukemia, 2021
- Bioluminescence imaging in mice with synthetic luciferin analogues2020
- DNA Fiber Analysis: Mind the Gap!2017
- p53 Activity Results in DNA Replication Fork ProcessivityCell Reports, 2016
- TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomesCancer, 2016
- p53 Maintains Genomic Stability by Preventing Interference between Transcription and ReplicationCell Reports, 2016
- Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency ModelComputational and Structural Biotechnology Journal, 2015
- Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cellsBiomedicine & Pharmacotherapy, 2013
- Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)Cancer Chemotherapy and Pharmacology, 2007